Stockscreener 앱 받기
8.33
4.14%
-0.36
시간 외 거래:
8.33
Agomab Therapeutics Nv Adr 주식(AGMB)의 최신 뉴스
What Does AgomAb (AGMB)'s +5.17% Surge Signal for the Sector? 2026-09-17Key Reversal Day - dars.gov.et
AgomAb Therapeutics Director Marino Garcia Granted 57,482 Stock Options - Kalkine Media
Director at Agomab Therapeutics NV (AGMB) receives 57K stock options - Stock Titan
Agomab Therapeutics (AGMB) awards long-dated stock options to director - Stock Titan
Agomab Shareholders Approve New Board Members and Pre-IPO Warrant Adjustment - TipRanks
ETFs Investing in AgomAb Therapeutics NV ADR Stocks - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS) - The Globe and Mail
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMcClellan Summation - siam.in
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMomentum Breakout Ideas - dars.gov.et
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionFast Moving Stocks - dars.gov.et
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - theglobeandmail.com
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Volatility & Greeks - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Latest SEC Filings - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
AGMB - Finviz
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewswire Inc.
1.35%
자본화:
|
볼륨(24시간):